中金辐照股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核说明 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 | 一、专项说明 | | | 1-2 | | --- | --- | --- | --- | | 二、附表 | 目 | 录 | 1 | 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地 址 （ l o c a t i o n ） ： 北 京 市 丰 台 区 丽 泽 路 2 0 号 丽 泽 S O H O B 座 2 0 层 20/F,Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China 电 ...

中金辐照股份有限公司 2024 年度跟踪报告 中信建投证券股份有限公司关于 | 保荐人名称：中信建投证券股份有限公司 | 上市公司简称：中金辐照 | | --- | --- | | 保荐代表人姓名：伍春雷 | 联系电话：0755-23953851 | | 保荐代表人姓名：李波 | 联系电话：0755-23953869 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2.督导公司建立健全并有效执行规章制度的情 | | | 况 | | | （1）是否督导公司建立健全规章制度（包括但 | | | 不限于防止关联方占用公司资源的制度、募集 | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 12 次 | | （2）公司募集资金项目进展是否与信息披露文 | 是 | | 件一致 ...

中信建投证券股份有限公司 关于中金辐照股份有限公司 首次公开发行股票并在创业板上市之保荐总结报告书 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证监会对保荐总结报告书相关事项进行的质 询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 | 保荐机构名称 | 中信建投证券股份有限公司 | | --- | --- | | 注册地址 | 北京市朝阳区安立路 66 号 4 号楼 | | 主要办公地址 | 深圳市福田区鹏程一路广电金融中心大厦 35 层 | | 法定代表人 | 刘成 | | 本项目保荐代表人 | 伍春雷、李波 | | 项目联系人 | 伍春雷 | | 联系电话 | 0755-23953851 | | 是否更换保荐人或其他情况 | 否 | 二、保荐机构基本情况 三、上市公司的基本情况 | 发行人名称 | 中金辐照股份有限公司 | | | --- | --- | --- | | 证券代码 ...

中金辐照股份有限公司 2024 年度独立董事述职报告 述职人：胡锡云 本人作为中金辐照股份有限公司（以下简称公司）第四 届董事会独立董事，严格按照《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等相关法律法规、规范性文件以及《公司 章程》《公司独立董事工作制度》等相关规定和要求，本着 对全体股东负责的态度，勤勉、忠实地履行独立董事职责， 认真审议董事会各项议案， 充分发挥了独立董事及各专业 委员会的作用，切实维护了公司和全体股东的利益。现将本 人 2024 年工作情况报告如下： 一、独立董事基本情况 本人胡锡云，1963 年出生，大学学历，研究员级高级会 计师、中国注册会计师。历任北京航天新概念软件有限公司 财务经理、财务总监，北京神舟航天软件技术有限公司财务 总监，中国航天空气动力技术研究院总会计师、航天彩虹 （SZ.002389）董事。2023 年 9 月至今任本公司独立董事。 二、独立董事履职情况 （一）出席董事会、 股东会情况 1 / 6 2024 年，公司召开了 10 次董事会和 3 次股东会 ...

中金辐照股份有限公司 2024 年度独立董事述职报告 述职人：郁红祥 本人郁红祥，1966 年出生，中共党员，法学硕士，一级 律师。历任唐山钢铁集团公司法律顾问，河北省唐山市中级 人民法院助理审判员、审判员、执行员、庭长，河北鸿翔律 师事务所主任、律师，百川股份有限公司独立董事，唐山金 融控股集团公司外部董事等。2023 年 9 月至今任本公司独立 董事。 二、独立董事履职情况 （一）出席董事会、股东会情况 1 / 5 2024 年，公司召开了 10 次董事会和 3 次股东会，本人 均出席了上述会议，认真履行了独立董事的义务，没有缺席、 没有委托他人出席或连续两次未亲自出席会议的情况。本着 勤勉尽责的态度，本人认真审阅董事会会议审议的相关材 料，积极参与议案讨论，依法表决，充分发挥独立董事的作 用。在股东会召开前，本人对需提交股东会审议的各项议案 均进行认真审阅，力求对全体股东负责。公司董事会和股东 会的召集和召开程序符合相关要求，重大经营决策事项和其 他重大事项方面均履行了相关审批程序，合法有效，未损害 股东，特别是中小股东的利益。本人对公司董事会的各项议 案均投了赞成票，无提出异议、反对或弃权的情形。 （ ...

中金辐照股份有限公司 2024 年度独立董事述职报告 述职人：靳云飞 本人作为中金辐照股份有限公司（以下简称公司）第四 届董事会独立董事，严格按照《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等相关法律法规、规范性文件以及《公司 章程》《公司独立董事工作制度》等相关规定和要求，本着 对全体股东负责的态度，勤勉、忠实地履行独立董事职责， 认真审议董事会各项议案， 充分发挥了独立董事及各专业 委员会的作用，切实维护了公司和全体股东的利益。现将本 人 2024 年工作情况报告如下： 本人靳云飞，1967 年出生，大学本科学历，中国人民大 学会计专业管理学硕士，高级经济师，注册会计师。历任国 家建材局管理干部学院大学老师、审计署驻国家建材局审计 局干部、国有大型企业监事会副处级专职监事、国有资产监 督管理委员会监事会正处级专职监事；中国广核集团所属中 广核铀业发展有限公司、中广核研究院有限公司、广东核电 合营有限公司、岭澳核电有限公司、岭东核电有限公司等 5 1 / 7 家二级企业总会计师，香港上市公司（中广 ...

根据《上市公司独立董事管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等要求，中金 辐照股份有限公司（以下简称"公司"）董事会就公司在任 独立董事靳云飞、胡锡云、郁红祥的独立性情况进行评估并 出具如下专项意见： 2025 年 4 月 29 日 经核查独立董事靳云飞、胡锡云、郁红祥的任职经历以 及签署的相关自查文件，上述人员未在公司担任除独立董事 以外的任何职务，也未在公司主要股东公司担任任何职务， 与公司以及主要股东之间不存在利害关系或其他可能妨碍 其进行独立客观判断的关系，因此，公司独立董事符合《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》中对独立董事独立性的相关 要求。 中金辐照股份有限公司董事会 中金辐照股份有限公司董事会 对独立董事独立性评估的专项意见 ...

Financial Performance - The company's revenue for Q1 2025 was ¥85,631,926.03, representing a 2.40% increase compared to ¥83,621,422.72 in the same period last year[4] - Net profit attributable to shareholders decreased by 13.52% to ¥25,801,991.28 from ¥29,836,447.36 year-on-year[4] - Basic and diluted earnings per share decreased by 13.54% to ¥0.0977 from ¥0.1130 in the same period last year[4] - The company's net profit for the current period is ¥26,413,668.98, a decrease of 14.4% compared to ¥30,804,107.18 in the previous period[15] - The total profit for the current period is ¥30,864,051.64, down from ¥36,145,484.91, reflecting a decline of 14.7%[15] - Operating profit decreased to ¥30,801,354.72 from ¥36,229,770.47, representing a decline of 15.0%[15] - The total comprehensive income attributable to the parent company is ¥25,801,991.28, down from ¥29,836,447.36, a decrease of 13.5%[15] Cash Flow and Investments - The net cash flow from operating activities fell by 27.36% to ¥30,783,675.88, down from ¥42,380,496.25 in the previous year[4] - The company incurred a net cash outflow from investing activities of ¥100,040,776.11, compared to a net outflow of ¥32,968,882.54 in the previous period[17] - The company received cash from operating activities totaling ¥85,147,796.26, a decrease of 7.9% from ¥92,029,397.07 in the previous period[17] Assets and Liabilities - Total assets increased by 2.15% to ¥1,169,205,425.89 compared to ¥1,144,613,365.91 at the end of the previous year[4] - Total liabilities decreased slightly to ¥153,639,659.29 from ¥155,461,268.29, a reduction of 1.17%[12] - The company's cash and cash equivalents decreased to ¥244,125,687.67 from ¥313,835,255.62, a decline of 22.14%[11] - Cash and cash equivalents at the end of the period decreased to ¥244,125,687.67 from ¥362,109,171.63, a decline of 32.6%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,079[7] - The largest shareholder, China National Gold Group Corporation, holds 54.20% of the shares[7] - Shareholders' equity attributable to the parent company rose by 2.72% to ¥974,270,333.15 from ¥948,468,341.87 at the end of the previous year[4] - The total equity attributable to shareholders rose to ¥974,270,333.15, an increase of 2.84% from ¥948,468,341.87[13] Operating Costs and Expenses - Total operating costs amounted to ¥54,492,699.21, up 13.41% from ¥48,064,108.10 in the prior period[14] - Research and development expenses increased to ¥7,091,505.96, reflecting a rise of 30.73% from ¥5,430,514.21 year-over-year[14] - The company reported a net credit impairment loss of ¥577,169.39, worsening from a loss of ¥216,521.40 in the previous period[14] - The company’s inventory increased to ¥1,010,540.48, up from ¥466,978.91, reflecting a growth of 116.66%[11] Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to ¥237,165.80 during the reporting period[5] - The company did not report any significant changes in non-recurring gains and losses during the period[5]

Financial Performance - The company's operating revenue for 2024 was CNY 358,512,458.03, representing a 3.99% increase compared to CNY 344,754,344.76 in 2023[19]. - The net profit attributable to shareholders for 2024 was CNY 108,872,277.12, a slight increase of 0.73% from CNY 108,077,920.58 in 2023[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 104,194,976.46, up 1.73% from CNY 102,423,177.89 in 2023[19]. - The net cash flow from operating activities for 2024 was CNY 194,010,811.93, an increase of 2.99% compared to CNY 188,380,816.34 in 2023[19]. - The total assets at the end of 2024 were CNY 1,144,613,365.91, reflecting a 3.85% increase from CNY 1,102,213,048.58 at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were CNY 948,468,341.87, a 3.53% increase from CNY 916,156,614.88 at the end of 2023[19]. - The basic earnings per share for 2024 were CNY 0.4124, up 0.73% from CNY 0.4094 in 2023[19]. - The diluted earnings per share for 2024 were also CNY 0.4124, reflecting the same increase of 0.73% from CNY 0.4094 in 2023[19]. - The weighted average return on equity for 2024 was 11.76%, a decrease of 0.31% from 12.07% in 2023[19]. Business Operations - The company’s primary business includes irradiation technology services, which are the main source of revenue and profit, focusing on sterilization services for medical products, food, and pharmaceuticals[31]. - The company has 120 gamma irradiation devices with a total design source capacity of 190 million curies as of the end of 2023, indicating significant operational scale in the radiation technology application industry[29]. - The company provides sterilization services for food packaging materials, including sterile packaging bags and storage bags, effectively extending shelf life and ensuring quality[37]. - The company has established a medical sterilization supply center, certified by ISO standards, providing reliable sterilization services for reusable medical instruments and surgical packs[41]. - The company’s irradiation technology services have shown an upward trend in profitability due to increasing demand and regional market expansion[44]. - The company has developed customized sterilization solutions based on client needs, utilizing various sterilization methods including gamma, electron beam, and ethylene oxide[47]. Market and Customer Base - The company operates in a rapidly expanding market, with a focus on the development of new technologies and services in the radiation processing sector[30]. - The main customer base consists of large companies with high disinfection and sterilization requirements, leading to stable and increasing demand as their business scales[50]. - The company has established long-term stable partnerships with over 30 Fortune 500 companies, including Johnson & Johnson and Asahi Kasei, enhancing its customer base[62]. - The revenue from irradiation technology services accounted for 92.91% of total revenue, amounting to CNY 333.09 million, which is a 4.99% increase from the previous year[70]. Research and Development - The company has invested in 49 new technology research projects and filed 42 new patents in 2024, enhancing its core technology capabilities[56]. - The company is focused on aligning its research and development efforts with international standards to facilitate market expansion and enhance competitiveness[80]. - The company has completed the development of the sterilization process for obstetric instruments, enhancing the irradiation effect and increasing irradiation business volume[81]. - The company is conducting research on the irradiation of diamonds to produce various colors, aiming to increase market share and economic benefits[81]. Financial Management and Investments - The company has committed investments totaling CNY 48 million, with CNY 19.95 million already invested, achieving a progress rate of 41.56%[99]. - The total investment amount for the reporting period was CNY 27,750,000.00, marking a 100% increase compared to the previous year[90]. - The company reported a net cash flow from financing activities of CNY -69,598,421.19, an improvement of 11.89% compared to CNY -78,989,210.39 in 2023[84]. - The company has established a dedicated fund management system to ensure that raised funds are used specifically for designated projects, enhancing regulatory compliance[198]. Corporate Governance - The company has established various specialized committees within the board to enhance governance and operational efficiency[121]. - The company ensures timely and accurate information disclosure, maintaining transparency with investors through designated media[125]. - The company has conducted its operations in accordance with the Company Law and other relevant regulations, maintaining a high level of corporate governance[118]. - The company has a complete and independent business system, with no reliance on the controlling shareholder for procurement or sales[132]. Social Responsibility and Environmental Management - The company has implemented measures to ensure compliance with environmental regulations, with no administrative penalties reported during the reporting period[184]. - The company actively participated in social responsibility initiatives, including providing 18,000 yuan in aid to underprivileged party members and grassroots workers[186]. - The company has established a robust environmental protection management system to fulfill its ecological responsibilities[185]. - The company reported a total of 20.54 million yuan in consumption assistance to support poverty alleviation efforts[186]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 1.46 CNY per 10 shares, totaling 38,544,276.96 CNY for the year 2024[175]. - The total cash dividend represents 100% of the distributable profit of 38,586,512.58 CNY[175]. - The company commits to distributing no less than 10% of the annual distributable profit in cash each year for the next three years[200]. - The board and independent directors will fully discuss and consider shareholder opinions, especially from public and small investors, in profit distribution decisions[200].

一、情况概述 证券代码：300962 证券简称：中金辐照 公告编号：2025-010 中金辐照股份有限公司关于子公司签署搬迁补偿 安置协议及补充协议的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 三、风险提示 本次交易对公司 2025 年或以后年度经营业绩影响视具体收回补偿 款时间及金额来确定，并以会计师事务所审计意见为准。在协议履行过 程中可能因国家政策、合作方履约能力等不可预见的或其它不可抗力因 素，从而影响协议的最终执行情况。公司将密切关注本事项进展情况， 及时履行信息披露义务。敬请广大投资者谨慎投资，关注投资风险。 特此公告。 中金辐照股份有限公司董事会 2025 年 4 月 7 日 因深圳市光明区光明街道白花片区连片产业用地土地整备工作的 需要，中金辐照股份有限公司（以下简称"公司"）的子公司深圳市金 鹏源辐照技术有限公司（以下简称"深圳金鹏源"）位于该片区的房屋、 临时建筑物、构筑物及其他附着物等（包含土地，下同）需进行搬迁。 深圳金鹏源拟与光明街道办、深圳市深业明瑞投资有限公司签署《搬迁 补偿安置协议》及《补充协议》，该事项已经公司第 ...